why choose us

300×250 Ad Slot

Drug FDA Status

Showing 110 of 144 result(s) (Page 11 of 15)
Drug Name: Agamree

Active Ingredient: vamorolone

Approval Date: 2023-10-26

Description: To treat Duchenne muscular dystrophy
Drug Trials Snapshot

Drug Name: Bimzelx

Active Ingredient: bimekizumab

Approval Date: 2023-10-17

Description: To treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Drug Trials Snapshot

Drug Name: Zilbrysq

Active Ingredient: zilucoplan

Approval Date: 2023-10-17

Description: To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive

Drug Name: Velsipity

Active Ingredient: etrasimod

Approval Date: 2023-10-12

Description: To treat moderately to severely active ulcerative colitis in adults

Drug Name: Rivfloza

Active Ingredient: nedosiran

Approval Date: 2023-09-29

Description: To lower urinary oxalate levels in patients 9 years and older with primary hyperoxaluria type 1 and relatively preserved kidney function

Drug Name: Pombiliti

Active Ingredient: cipaglucosidase alfa-atga

Approval Date: 2023-09-28

Description:

To treat late-onset Pompe disease
Drug Trials Snapshot

Drug Name: Exxua

Active Ingredient: gepirone

Approval Date: 2023-09-22

Description: To treat major depressive disorder

Drug Name: Ojjaara

Active Ingredient: momelotinib

Approval Date: 2023-09-15

Description: To treat intermediate or high-risk myelofibrosis in adults with anemia

Drug Name: Aphexda

Active Ingredient: motixafortide

Approval Date: 2023-09-08

Description: To use with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma
Drug Trials Snapshot

Drug Name: Veopoz

Active Ingredient: pozelimab-bbfg

Approval Date: 2023-08-18

Description: To treat patients 1 year old and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease

300×250 Ad Slot